NCT06939569
An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Recruiting · Not specified · Shanghai East Hospital · registry updated 2025-04-23
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has increased dramatically in China, and it will become a common disease of digestive system in China. Mesenteric adipose tissue hyperplasia indicates disease activity in IBD patients, and abnormal lipid metabolism plays an important role in the pathogenesis of IBD. In addition to intestinal symptoms, nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction associated fatty liver disease (MASLD), has become the most common extraintinal manifestation in IBD patients. What are the similarities and differences between IBD patients with and without MASLD? Does the occurrence and severity of MASLD affect the clinical efficacy of IBD and increase the adverse outcome of IBD? There are no relevant studies to date. We have previously completed the construction of a cohort of 290 IBD patients using the IBD patient database and biobank of Dongfang Hospital, based on which we completed a cohort study on the effect of small intestinal bacterial overgrowth on IBD disease activity....
Inclusion
- Subjects aged over 18 years (including borderline values), of either sex.
- Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD;
- Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.
Exclusion
- Subjects with incomplete clinical data;
- Subjects can not to cooperate with follow-up, and refuse to sign the informed consent;
- Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women;
- Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.